Genomics England has selected WuXi NextCODE as its first partner for the clinical interpretation of cancer samples processed by the massive sequencing project it is overseeing. WuXi NextCODE is also applying its technology to the interpretation of genomic data from rare disease patients.
The FDA is trying to learn more about virtual clinical trials, the bring-your-own-device (BYOD) model of provisioning and other aspects of today's tech-enabled research environment. The regulator has set up a docket to gather feedback on how researchers are using technology and what barriers are stopping more widespread adoption.
The software, called PKPlus, is seen by Simulations Plus as a way to step up competition in the market for noncompartmental analysis software.
In recent years, the use of wearables in clinical trials has gone from being an attractive but untested idea to an emerging part of the research toolkit. Now, Bloomberg has tallied up just how many trials are building the devices into their protocols: 299.
Immuno-oncology player Adaptimmune has dipped into the ranks of its Big Pharma partner GlaxoSmithKline to find a leader for its biometrics team. The move sees Trupti Trivedi join Adaptimmune as VP, head of biometrics.
Thermo Fisher has stepped up its attempts to capture the targeted sequencing market with the introduction of the Ion S5 system. The next-generation sequencing system is pitched squarely at clinical trials and other fields in which a quick, affordable snapshot of a panel of genes is needed.
The movement to shift informed consent in clinical trials from paper forms to electronic devices has notched up another victory. Mytrus and an unnamed top-10 pharma company made the advance by becoming the first organizations to win clearance to use e-consent in a trial in the United Kingdom.
Boehringer Ingelheim has upgraded to the latest version of InnovoCommerce's innovoPOINT.
BioClinica has expanded the range of ways customers can access its suite of eClinical tools. The new service, dubbed the BioClinica eHealth Cloud, allows biopharma companies and CROs to run Express EDC, Trident RTSM and other pieces of trial software on public, private, managed or custom cloud infrastructure.
The move marks the first time a study run using the ResearchKit platform--which made a splash earlier this year when it facilitated rapid enrollment in a handful of trials--has started accepting participants from outside the U.S.